XORTX Therapeutics (XRTX) Income from Non-Controlling Interests (2023 - 2026)
XORTX Therapeutics' (XRTX) quarterly Income from Non-Controlling Interests came in at -$717700.0 in Q2 2025, down 522.01% YoY from $170066.0 in Q2 2024, and down 522.01% on a QoQ basis from $170066.0 in Q2 2024.
XORTX Therapeutics (XRTX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$717700.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 7,816.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -717,700.00 |
| Jun 30, 2024 | 170,066.00 |
| Sep 30, 2023 | -1.33 Mn |
| Jun 30, 2023 | -1.69 Mn |
| Mar 31, 2023 | -1.83 Mn |